Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Healthcare Closes Second Venture Fund with $290 Million

publication date: Dec 15, 2015
WuXi Healthcare closed WuXi Healthcare Ventures II, L.P. with funding of $290 million, well above the target of $200 million. Following the format of its first fund, WXHVII will identify early stage investments, usually cross-border, adopting a strategy of "find in U.S. and build in China." Several of WuXi's investments, such as diagnostics company Foundation Medicine, have been strategic, establishing relationships with companies that later became partners with WuXi AppTec, the CRO, which was reported to have made a $50 million anchor investment in the new fund. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital